Tuesday, March 19, 2024 1:20:21 PM
We'll see if that proves to be the case. It would definitely mean admitting defeat on the course that Pfizer, Moderna, and the FDA have been mandating.
And in the UK, I see what could be further recognition that the wrong covid treatment course was chosen. The UK announced that the fourth module of their national Covid-19 Inquiry will be rescheduled.
start at the beginning. this section of information concludes at the 4 minute mark, and goes on to an important discussion of 'Disease X.'
The Daily Mail, however, reported that the continued probe into the covid vaccines will be postponed indefinitely. So again, we'll see what proves to be the case. Maybe we'll even see mRNA abandoned by Pfizer, Moderna, and the FDA, in favor of traditional vaccines, like Nuvaxovid. Or maybe those companies will just abandon the covid market, which could by then be held by Humanigen/Novavax.
I'm tempted to start an additional post at this point, but I want to speak more about the video that you have open already. Continue watching at minute 4.
Our current failure stems from unauthorized gain-of-function research, conducted without utilizing the required bio-containment measures.
Research into Disease X also requires gain-of-function utilization, to possibly produce another novel coronavirus, which I think could be the Pangolin Coronavirus GX_P2V, as I'll feature in the following video.
You can start at minute mark 10:40, if you don't have 26 minutes to watch the whole video.
So, is this the reason the UK's Covid-19 Inquiry was basically put on hold, to begin preparations for the next biological threat?
I like Dr. John Campbell, who is not an MD, by the way. He has a PhD, and teaches clinical nursing. But I sure would like to see him discuss lenzilumab with Durrant and Dale. They are the world 's experts here, in my opinion, and they ought to spearhead, with other doctors (not government agents), where we go from here. It's imperative, when faced with a virus that has a 100% mortality rate, that the virus is denied access to targeted receptor cells.
"In patients diagnosed with covid pneumonia, and treated with lenzilumab, what is the recurrence rate of those patients presenting with SARS-CoV-2 nucleocapsid proteins after treatment?"
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM